Currency In USD
| Previous Close | 3.22 |
| Open | 3.03 |
| Day High | 3.3 |
| Day Low | 3.03 |
| 52-Week High | 8.48 |
| 52-Week Low | 1.03 |
| Volume | 7,589.89 |
| Average Volume | 4.65M |
| Market Cap | 14.27M |
| PE | -2.52 |
| EPS | -1.31 |
| Moving Average 50 Days | 3.11 |
| Moving Average 200 Days | 2.15 |
| Change | 0.08 |
Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board
GlobeNewswire Inc.
Feb 17, 2026 12:00 PM GMT
–Received Positive Pre-Investigational New Drug (“IND”) Written Feedback from the U.S. Food and Drug Administration (“FDA”)– –Clinical Advisory Board (“CAB”) Includes Key Leaders across Neuropsychiatry, Anesthesiology, and Clinical Development– –Rema
Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression
GlobeNewswire Inc.
Jan 05, 2026 9:01 PM GMT
– Cyclerion Strengthens Development of Closed-Loop Anesthetic Platform through Strategic Collaboration Agreement with Medsteer – – Comprehensive Business Update and Path to Initiating Phase 2 Proof-of-Concept (“POC”) Study in the Second Half of 2026
Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company
GlobeNewswire Inc.
Sep 23, 2025 8:01 PM GMT
– Cyclerion Relaunches, Advancing a Phase 2–Ready Program for Millions Living with Treatment-Resistant Depression Through MIT License Agreement – – Webcast to be held September 24, 2025 at 10:30 a.m. ET – CAMBRIDGE, Mass., Sept. 23, 2025 (GLOBE NEW